...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neurosurgical focus >Enhanced therapeutic agent delivery through magnetic resonance imaging–monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclinical status
【24h】

Enhanced therapeutic agent delivery through magnetic resonance imaging–monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclinical status

机译：通过磁共振成像监测聚焦的超声血脑屏障破坏来增强治疗药物的输送，以治疗脑肿瘤：当前临床前状况的概述

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Malignant glioma is a severe primary CNS cancer with a high recurrence and mortality rate. The current strategy of surgical debulking combined with radiation therapy or chemotherapy does not provide good prognosis, tumor progression control, or improved patient survival. The blood-brain barrier (BBB) acts as a major obstacle to chemotherapeutic treatment of brain tumors by severely restricting drug delivery into the brain. Because of their high toxicity, chemotherapeutic drugs cannot be administered at sufficient concentrations by conventional delivery methods to significantly improve long-term survival of patients with brain tumors. Temporal disruption of the BBB by microbubble-enhanced focused ultrasound (FUS) exposure can increase CNS-blood permeability, providing a promising new direction to increase the concentration of therapeutic agents in the brain tumor and improve disease control. Under the guidance and monitoring of MR imaging, a brain drug-delivery platform can be developed to control and monitor therapeutic agent distribution and kinetics. The success of FUS BBB disruption in delivering a variety of therapeutic molecules into brain tumors has recently been demonstrated in an animal model. In this paper the authors review a number of critical studies that have demonstrated successful outcomes, including enhancement of the delivery of traditional clinically used chemotherapeutic agents or application of novel nanocarrier designs for actively transporting drugs or extending drug half-lives to significantly improve treatment efficacy in preclinical animal models.
机译：恶性神经胶质瘤是一种严重的原发性中枢神经系统癌，具有较高的复发率和死亡率。当前的外科手术减量结合放射疗法或化学疗法的策略不能提供良好的预后，肿瘤进展控制或患者生存期的改善。血脑屏障（BBB）通过严格限制药物向大脑的输送，成为化学疗法治疗脑肿瘤的主要障碍。由于它们的高毒性，化学疗法药物不能通过常规递送方法以足够的浓度给药以显着改善脑肿瘤患者的长期生存。通过微泡增强聚焦超声（FUS）暴露对BBB的暂时破坏可以增加CNS的血液渗透性，为增加脑肿瘤中治疗剂的浓度并改善疾病控制提供了有希望的新方向。在MR成像的指导和监视下，可以开发出大脑药物输送平台来控制和监视治疗剂的分布和动力学。最近在动物模型中证明了FUS BBB破坏成功地将多种治疗分子递送到脑肿瘤中。在本文中，作者回顾了许多关键研究，这些研究已经证明了成功的结果，包括增强传统临床使用的化学治疗剂的递送或新颖的纳米载体设计用于主动转运药物或延长药物半衰期以显着提高治疗效果。临床前动物模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号